Otsuka Pharmaceutical Co., Ltd.

This study is testing the long-term safety and effectiveness of a medication called SEP-363856 for adults with schizophrenia. About 100 participants will take the drug daily for 52 weeks while researchers monitor for side effects. The goal is to see if this treatment can help con…

This study is testing a new, once-daily capsule called EB-1020 to see if it can help control the core symptoms of ADHD in children and teenagers. It will compare two different doses of the medication against a placebo (a capsule with no active drug) over six weeks. The goal is to…

This study aims to check the long-term safety of a daily medication called EB-1020 for children and teenagers with ADHD. It will follow about 180 participants for 52 weeks to see how they tolerate the treatment. The main goal is to monitor for any side effects that may occur duri…

This study is a survey to monitor the safety of the drug LUPKYNIS in 400 patients with lupus nephritis (kidney inflammation from lupus) under real-world conditions. It will collect information on any side effects, how the drug is used, and its effectiveness in everyday practice. …